Plasma complement proteins as biomarkers and therapeutic targets in chronic kidney disease: a Mendelian randomization analysis.

ABSTRACT:

Background

Chronic Kidney Disease (CKD) is a progressive condition leading to End-Stage Kidney Disease (ESKD). With limited treatment options, identifying biomarkers related to CKD onset and progression is essential. The complement system, an immune network, has shown potential involvement in CKD pathogenesiss. This study investigates the causal role of diverse plasma complement proteins in CKD and its clinical types to discover new biomarkers and therapeutic targets.

Method

Using two-sample Mendelian randomization (MR), we examined the causal relationships between 28 plasma complement proteins and CKD outcomes. Plasma complement levels were sourced from a genome-wide association studies involving 35,559 Icelandic individuals, CKD outcome sourced from the FinnGen R11 and kid

SUBMITTER: Xu YP 

PROVIDER: S-EPMC12272671 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature